Biotechnology Companies in Norway

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.

Cryogenetics offers services and technology for an effective fish reproduction. Our main service has traditionally been the cryopreservation of fish milt. Cryopreservation is a powerful tool for preservation of genetic diversity in wild species and as an integral part of both commercial aquaculture and other fish breeding programs. In addition to cryopreservation and storage services the company also offers several other products and services helping to secure more effective fish reproduction. These include technology for fresh storage of milt, milt quality evaluation and gender testing of fingerlings.